A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514

NCT05264038 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Cachexia

Interventions

DRUG: OC514 (Low dose)
DRUG: OC514 (Mid dose)
DRUG: OC514 (High dose)
OTHER: Placebo

Sponsor

Oncocross Australia Pty Ltd.